

CURRICULUM VITAE
Colleen R. Kelly M.D. FACG, AGAF

Professional Address: Women's Medicine Collaborative
146 West River Street, Suite 1H
Providence, RI 02904
(401) 793-7080
(401) 793-7801

Electronic mail: ckelly2@lifespan.org
colleen_r_kelly@brown.edu
ckelly91@brown.edu

EDUCATION

Undergraduate B.A., Chemistry, 1992-1995
Cornell University
Ithaca, New York

Miami University, 1991-1992
Oxford, Ohio

Medical School Doctor of Medicine, 1995-1999
The Ohio State University College of Medicine
Columbus, Ohio

POSTGRADUATE TRAINING

Residency Internal Medicine, 1999-2002
Boston University Medical Center
/
Boston, Massachusetts

Fellowship Gastroenterology, 2003-2006
Brown/Rhode Island Hospital
Providence, Rhode Island

POSTGRADUATE HONORS AND AWARDS

Beckwith Family Teaching Award 2019
Warren Alpert Medical School of Brown University

| | |
|--|------------|
| American Gastroenterological Association Awarded Fellowship | 2019 |
| Rhode Island Monthly Magazine: Top Doctor | 2017 |
| American College of Gastroenterology: Governors' Award for Excellence in Clinical Research (See Abstract section) | 2013 |
| Awarded Fellowship | 2014 |
| American College of Gastroenterology: Governors' Award for Excellence in Clinical Research (See Abstract section) | 2013 |
| Certificate of Recognition for Exemplary Teaching: BIOL 3673 IMS IV: Gastroenterology, The Warren Alpert Medical School of Brown University | 2010, 2020 |
| Landacre Student Research Society-Ohio State University-inducted in April | 1997 |
| Samuel J. Roessler Memorial Medical Research Scholarship | 1996 |

MEDICAL LICENSURE

Rhode Island: #12090
Massachusetts: 2001-2004

BOARD CERTIFICATION

American Board of Internal Medicine (212933):
Internal Medicine 8/2002
Gastroenterology 11/2006, recertified 11/2016, MOC
USMLE Step 1: June 1997, 236
USMLE Step 2: August 1998, 261
USMLE Step 3: October 2000, 260

ACADEMIC APPOINTMENTS

| | |
|--------------|--|
| 2017-present | Associate Professor of Medicine Research Scholar Track Alpert Medical School of Brown University |
| 2014-2017 | Assistant Professor of Medicine Research Scholar Track Alpert Medical School of Brown University |
| 2010-2014 | Clinical Assistant Professor of Medicine Alpert Medical School of Brown University |

HOSPITAL APPOINTMENTS

| | |
|--------------|---|
| 2017-present | Gastroenterologist, The Miriam Hospital; Lifespan Physician Group Gastroenterology, Providence, RI |
| 2011-2017 | Gastroenterologist, The Miriam Hospital; Women's Medicine Collaborative, Providence, RI |
| 2006-present | Gastroenterologist, Rhode Island Hospital, Providence, RI |
| 2006-2017 | Gastroenterologist, Women and Infants Hospital, Providence, RI. |
| 2006-2010 | Consulting Privileges, Roger Williams Hospital, Providence, RI |
| 2002-2003 | Hospitalist, Quincy Medical Center, Quincy, MA |

OTHER APPOINTMENTS AND COMMITTEES

UNIVERSITY SERVICE

| | |
|-----------|---|
| 2019-2022 | Medical Faculty Executive Committee (elected) Warren Alpert Medical School of Brown University |
|-----------|---|

HOSPITAL AND OTHER COMMITTEES AND TASK FORCES

| | |
|-----------|---|
| 2019-2020 | Rhode Island Department of Health <i>C. difficile</i> Task Force |
| 2017-2018 | Endoscopy Process Improvement Project Steering Committee Rhode Island Hospital |
| 2012-2013 | Miriam Hospital-Patient Care Committee |

SYMPOSIA AND CONFERENCE PLANNING

| | |
|------|--|
| 2020 | Gut Microbiota for Health World Summit. Madrid, Spain -Scientific planning committee |
| 2020 | Malibu Microbiome Meeting. Malibu, California. -planning committee |
| 2019 | American College of Gastroenterology Eastern Regional Postgraduate course. Washington, D.C. -Course director |
| 2019 | Gut Microbiota for Health World Summit. Miami, Florida -Scientific planning committee |
| 2018 | Gut Microbiota for Health World Summit. Rome, Italy -Scientific planning committee |
| 2017 | Gut Microbiota for Health World Summit. Paris, France |

- Scientific planning committee
- 2016 Gut Microbiota for Health World Summit. Miami, Florida
-Scientific planning committee
- 2015 Gut Microbiota for Health World Summit. Barcelona, Spain.
-Scientific planning committee
- 2012 *Clostridium difficile* Symposium. The Miriam Hospital. 09/19/12
-Course director
-Chair: Planning committee

PROFESSIONAL SOCIETY MEMBERSHIPS/COMMITTEES AND APPOINTMENTS

- 2003-present American College of Gastroenterology
 - Women in Gastroenterology Committee 2013-2018
 - Grassroots initiative and work-life balance subcommittee
 - Co-Chair, ACG Women in GI Circle
 - *ad hoc* FMT Workgroup 2013
 - Awarded fellowship, January 2014
 - Research Committee 2020-2023
- 2003-present American Gastroenterological Association
 - *ad hoc* FMT FDA Committee 2013
 - FMT Spokesperson 2013-20
 - Center for Gut Microbiome Research and Education Scientific Advisory Board (2014-2017)
 - FMT Registry Steering Committee
 - Media and Communications Subcommittee
 - AGA Institute Council: Microbiome and Microbial Diseases of the Gastrointestinal Tract
 - Nominating committee (elected 2016)
 - AGA Council: Basic and Clinical Intestinal Disorders.
 - Vice Chair, elected 2020
- 2012-19 Rhode Island Medical Society
- 2003-2010 Rhode Island GI Society
- 2003-2009 American Society for the Study of Liver Diseases
- 1999-2003 Massachusetts Medical Society
 - Resident Representative for the Committee on Quality of Medical Practice (2000)
- 1995-2003 American Medical Association
- 1995-2003 American College of Physicians
- 1995-1999 American Medical Students Association

PROFESSIONAL AND ACADEMIC SERVICE

International Editorial Board Member

Alimentary Pharmacology & Therapeutics (2014-2017)

Ad hoc reviewer for:

The National Institutes of Health/NIAID (2014-2017, 2019,2020)

Gut Microbes (2016)

Lancet (2016)

Clinical Gastroenterology and Hepatology (2016,2017)

American Journal of Gastroenterology (2016)

Veterinary Medicine: Research and Reports (2016)

Gut Microbe (2015,2017-18)

BMJ Case Reports (2015)

AGA/DDW Abstracts (2015)

Emerging Infectious Diseases (2014, 2016)

Veterans affairs Evidence-based Synthesis Program (2014)

The Journal of Intensive Care Medicine (2014)

The New England Journal of Medicine (2014, 2017)

JAMA (2014, 2018)

Gastroenterology (2013-17, 2020)

American Journal of Transplantation (2013)

Scandinavian Journal of Infectious Diseases (2013)

Therapeutic Advances in Gastroenterology (2012)

Journal of Clinical Gastroenterology (2012)

Antimicrobial Agents and Chemotherapy 2012-2014

Broad Foundation of the CCFA: Medical Research Program Grant Reviewer (2012-16)

Journal of Inflammatory Bowel Disease (2012)

Mayo Clinic Proceedings (2017)

Inflammatory Bowel Diseases (2016-18)

The Netherlands Organization for Health Research and Development (2017)

Science (2016)

Open Forum Infectious Diseases (2017-18)

**ADVISORY BOARDS, PLANNING COMMITTEES, WORKING GROUPS AND
CONSENSUS CONFERENCES**

June 2019 Rome II FMT Consensus Conference. Stool Banks for FMT in Clinical Practice.
Rome, Italy
Working Group V-Registries and Ethical Issues

June 2019 Consensus Working Group for Faecal Microbiota Transplantation in Australia.
Sydney, Australia

2018-present Steering Committee
RESTORE trial: FMT for *C difficile* in Solid Organ Transplant Recipients
NIAID; National Clinical Trial. NCT03617445

- 2017-2018 Multinational ROME FMT Consensus Conference
 North American Group Leader
 Working group V liaison
- 2014-2017 American Gastroenterological Association
 Center for Gut and Microbiome Research and Education
 Scientific Advisory Board
- 2014-present Gut Microbiota for Health Summit
 Scientific Committee
- 2014-present OpenBiome
 Clinical Advisory Board
 Research Methodology Subcommittee
- 2016 CDC: National Healthcare Safety Network
C difficile infection Risk Adjustment Experts Group
- 2015-2016 Microbiome Transplantation: Recommendations for a Regulatory
 Framework. PI: Hoffmann
 Working Group Member
- 2013-2015 The Fecal Transplant Foundation
 Advisory Board
- 2010 Management of Female Pelvic Floor Disorders: The Team Approach. Women
 and Infants Hospital. March 13th
 -Planning committee

PUBLICATIONS LIST

Complete list of my published work in MyBibliography:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/1zmOJ07eRffkE/bibliography/44192192/public/?sort=date&direction=ascending>

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Marcella C, Cui B, **Kelly CR**, Ianiro G, Cammarota G, Zhang F. Systematic Review: The Global Incidence of Faecal Microbiota Transplantation Related Adverse Events from 2000 to 2020. *Alimentary Pharmacology and Therapeutics* 2020, accepted.
2. Allegretti JR, **Kelly CR** Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent *C. difficile* Infection. *Inflammatory Bowel Diseases* 2020, accepted.
3. **Kelly CR**, Chen EF, Grinspan AM, et al. Fecal Microbiota Transplant is Highly Effective in Real-World Practice: Initial Results from the FMT National Registry. *Gastroenterology* 2020, accepted.

4. Allegretti , **Kelly CR**, Grinspan A, et al. Inflammatory Bowel Disease and Recurrent *C. difficile* Infection: Outcomes after Fecal Microbiota Transplantation (ICON). *Gastroenterology* 2020, accepted.
5. Ianiro G, Mullish B, **Kelly CR**, et al. Reorganization of faecal microbiota transplant services during the COVID-19 pandemic. *Gut* 202 Jul 3 epub.
6. Ianiro G, Mullish BH, Kelly CR. Screening of faecal microbiota transplant donors during the COVID-19 Outbreak: Suggestions for Urgent Updates form and International Expert Panel. *Lancet Gastroenterology and Hepatology* 2020; 5:430-432.
7. Allegretti JR, Elliot RJ, Ladha A, Njenga M, Warren K, O'Brien K, Budree S, Osman M, Fischer M, Kelly CR, Kassam Z. Stool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation. *Gut Microbes* 2020 Nov 1;11(6):1806-08
8. Allegretti JR, Mehta SR, Kassam Z, Kelly CR, Kao D, Xu H, Fischer M. Risk factors that predict the failure of multiple fecal microbiota transplants for *Clostridioides difficile* infection. *Dig Dis Sci* 2020 Mar 13, epub
9. Sangha M, **Kelly CR**, Rauschert L. Liver and Gallbladder Herniation. *Gastroenterology* 2020 Jun;158(8):2058-2060.
10. **Kelly CR**, Paramsothy S, et al. Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice [published online ahead of print, 2020 Feb 11]. *Gut*. 2020 PMID:32047093
11. Ekekezie C, Perler B, Simmons S, Wexler A, **Kelly CR**. Understanding the Scope of DIY FMT. *American Journal of Gastroenterology*, 2010 Jan 10 (epub) PMID:31972620
12. Perler B, Chen B...**Kelly CR**. Long term efficacy and safety of fecal microbiota transplant for treatment of *C. difficile* infection. *J Clin Gastro* 2020 Jan 31 (epub) PMID:32011405
13. Ianiro G, Cammarota G, **Kelly CR**, et al. "International Consensus Conference on stool banking for faecal microbiota transplantation in clinical practice" *Gut* December 2019; 68 (12), 2111-2121 PMID: 31563878
14. Kassam Z, Dubois N, Ramakrishna B, et al. Donor Screening for Fecal Microbiota Transplantation. *N Engl J Med*. 2019;381(21):2070–2072.
15. **Kelly CR**, Fischer M, Grinspan A, Allegretti JR. Patients Eligible for Trials of Microbiota-based Therapeutics do not Represent the Population with Recurrent *C difficile* Infection. *Clinical Gastroenterology and Hepatology* 2019 Jun 27 (epub). PMID: 31254675
16. Allegretti JR, Mullish BH, **Kelly CR**, et al. The evolution of the use of Faecal Microbiota Transplantation and emerging therapeutic indications. *Lancet* 2019; 394 (10196), 420-431.
17. Allegretti JR, Kassam Z, Fischer M, **Kelly C**, Chan WW. Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of *Clostridium difficile* by Fecal Microbiota Transplantation (FMT). *J Clin Gastroenterol* 2019 Mar 13 (epub)

18. Krajicek E, Fischer M, Allegretti JR and **Kelly CR**. Fecal Microbiota Transplantation: Nuts and Bolts and How to. *Clinical Gastroenterology and Hepatology* 2019 Jan;17(2):345-352
19. Azimirad M, Yadegar A, Asadzadeh Aghdai H, **Kelly CR**. Enterotoxigenic *Clostridium perfringens* Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent *Clostridium difficile* Infection: A Neglected Agent in Donor Screening. *J Crohns Colitis*. 2019;13(7):960–961.
20. Santiago M, Eysenbach L, Allegretti J, Aroniadis O, Brandt LJ, Fischer M, Grinspan A, **Kelly C**, et al. Microbiome Predictors of Dysbiosis and VRE Decolonization in Patients with Recurrent *C difficile* Infections in a Multi-Center Retrospective Study. *AIMS Microbiology* 2019 5(1):1-18.
21. Jamot S, Raghunathan V, Patel K, **Kelly CR**, Lim SH. Factors Associated with the Use of Fecal Microbiota Transplant in Patients with Recurrent *Clostridium difficile* Infections. *Infection Control & Hospital Epidemiology*, 2018 Mar;39(3):302-306.
22. Allegretti J, Kassam Z, Fischer M. **Kelly CR**. The 5D Framework: A Clinical Primer for Fecal Microbiota Transplantation to Treat *Clostridium difficile* infection. *Gastrointestinal Endoscopy*. 2018 Jan;87(1):18-29.
23. Browne AS, **Kelly CR**. Fecal Transplant in Inflammatory Bowel Disease. *Gastroenterol Clin North Am*. 2017 Dec;46(4):825-837
24. Rebello D, Wang E, Yen E, Lio P, **Kelly CR**. Unexpected Benefits: Hair Growth in Two Alopecia Patients after Fecal Microbiota Transplant. *ACG Case Reports Journal* 2017 Sep 13;4:e107
25. Allegretti J, Eysenbach LM, El-Nachef, Fischer MD, **Kelly C**, Kassam Z. The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present and Future. *Inflammatory Bowel Disease* 2017.
26. Kelly CR, Kim AM, Laine L, Wu GD. The AGA’s Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics. *Gastroenterology*. 2017 Mar;152(4):681-684.
27. Sadowsky MJ, Staley C, Heiner C, Hall R, **Kelly CR**, Brandt L, Khoruts, A. Analysis of Gut Microbiota – an ever changing landscape. *Gut Microbes* 2017 May 4;8(3):268-275.
28. Staley C, **Kelly C**, Brandt L, et al. Complete Microbiota Engraftment is not Essential for Recovery from Recurrent *Clostridium difficile* Infection following Fecal Microbial Transplantation. *mBio*, Accepted November 21st 2016.
29. **Kelly CR**. Khoruts A, Staley C, et al. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent *Clostridium difficile* Infection: A Randomized Trial *Ann Intern Med*; *Ann Intern Med*. 2016 Nov 1;165(9):609-616. PMID: 27547925
30. Fischer M, Kao D, **Kelly CR**, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory *Clostridium difficile* infection in patients with inflammatory bowel disease. *Inflammatory Bowel Diseases* 2016 Oct; 22(10):2402-9. PMID: 27580384

31. Fischer M, Kao D, Mehta S, Martin T, Dimitry J, Keshteli A, Cook G, Phelps E, Sipe B, Xu H and **Kelly CR**. Predictors of Failure after Fecal Microbiota Transplantation for the Therapy of *Clostridium Difficile* Infection: A Multicenter Study. *Am J Gastro* 2016 Jul; 111(7):1024-31. PMID: 27185076
32. Khanna S, Pardi DS, **Kelly CR**, et al. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent *Clostridium difficile* Infection. *J Infect Dis* 2016 Jul 15; 214(2):173-81. PMID: 26908752
33. Jackson M, Olafson S, Machan J. **Kelly C**. The Spectrum of Alternate Diagnoses and Outcomes in Patients Referred for *C. difficile* Infection. *J. Clin Gastroenterol*. 2015 Nov 12 [Epub]. PMID: 26565971
34. Agrawal M, Aroniadis O, Brandt LJ, **Kelly C**, et al. The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated *Clostridium difficile* Infection in 146 Elderly Individuals. *J Clin Gastroenterol*. 2015 Aug 26. [Epub]
35. Mao E, **Kelly CR**, Machan J. Racial Differences in *Clostridium difficile* Risk are Attributable to Disparities in Healthcare Access. *Antimicrobial Agents and Chemotherapy*. 2015 Oct; 59(10):6283-7.
36. **Kelly CR**, Kahn S, Kashyap P, et al. Update on FMT 2015: Indications, Methodologies, Mechanisms and Outlook. *Gastroenterology* 2015; 149(1):223-37. PMID: 25982290
37. Aroniadis O, Brandt L, Greenberg A, Borody T, **Kelly C**, et al. Long-term follow-up study of fecal microbiota transplantation (FMT) for severe and/or complicated *Clostridium difficile* infection (CDI): a multicenter experience. *Journal of Clinical Gastroenterology*. 2015 Jun 23 [Epub].
38. Edelstein CA, Kassam Z, Daw J, Smith MB, **Kelly CR**. "The Regulation of Fecal Microbiota for Transplantation: An International Perspective for Policy and Public Health" *Clinical Research and Regulatory Affairs*. 2015; 32 (3), 101-109
39. Alang N. **Kelly C**. Weight Gain after Fecal Microbiota Transplantation. *Open Forum Infectious Diseases*. Winter 2015. PMID: 26034755
40. **Kelly C**, Ihunnah C, Fischer M, et al. Fecal Microbiota Transplant for Treatment of *Clostridium difficile* Infection in Immunocompromised Patients. *Am J Gastro* 2014; 109(7):1065-71. PMID: 24890442
41. Smith M, **Kelly C**, Alm E. How to Regulate Faecal Transplants. *Nature* 2014; 506:290-91. PMID: 24558658
42. **Kelly C**, Kunde, S, Khoruts A. Guidance on Preparing an Investigational New Drug Application for Fecal Microbiota Transplantation Studies. *Clinical Gastroenterology and Hepatology* 2014;12:283-288. PMID: 24107393
43. De Leon L, Watson J. **Kelly C**. Transient Flare of Ulcerative Colitis after Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection. *Clin Gastroenterology and Hepatology* 2013. Aug; 11(8):1036-8. PMID: 23669309

44. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, **Kelly C**, Park T, Stollman N, Rohlke F, Surawicz C. Long-term Follow-up of Colonoscopic Fecal Microbiota Transplant for Recurrent *Clostridium difficile* Infection. *Am J Gastro* 2012; 107:1079-87. PMID: 22450732
45. **Kelly C**, deLeon L, Jasutkar N. Fecal Microbiota Transplantation for Relapsing *Clostridium difficile* Infection in 26 Patients: Methodology and Results. *J Clin Gastroenterol*. 2012 Feb;46(2):145-9. PMID: 22157239
46. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzo MA, **Kelly C**, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C. Treatment of *Clostridium difficile* Infection by Fecal Microbiota Transplantation. *Clin Gastroenterology Hepatology* 2011 Dec;9(12):1044-9. PMID: 21871249
47. Yao M, Lam EC, **Kelly CR**, et al. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. *British Journal of Cancer* 90(3):712, 2004
48. Yao M, Kargman S, Lam EC, **Kelly CR**, Zheny Y, Luk P, Kwong E, Evans JF, Wolfe MM: "Inhibition of Cyclooxygenase-2 by Refecoxib Attenuates the Growth and Metastatic Potential of Colorectal Carcinoma in Mice." *Cancer Research* 63:586-592, February 1, 2003.
49. **Kelly C**, Jankowich M: "Obese Diabetic Patients Have Increased Volume, Decreased pH Gastric Contents Compared to Obese Non-Diabetic Patients." *Anesthesiology* supplement 87(3A):A1023, September 1997.

EDITORIALS AND OTHER PEER-REVIEWED PUBLICATIONS

1. **Kelly CR**, Laine L, Wu G. Monitoring Fecal Microbiota Transplantation Practice in a Rapidly Evolving Health and Regulatory Environment. Commentary in *Gastroenterology* 2020 Aug 26
2. Ianiro G, Mullish B, **Kelly CR**, et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from and international expert panel. *Lancet Gastroenterology and Hepatology* 2020. Vol 5(5): 430432.
3. Kelly CR, Kahn SA. Is it Unethical to conduct placebo-controlled trials of faecal microbiota transplantation for recurrent *Clostridioides difficile* infection? *Lancet Gastroenterology and Hepatology* 2020. Vol 5(5):432-33.
4. Sangha M, **Kelly CR**. "Rare Case of Liver and Gallbladder Herniation" Clinical challenge and Image. *Gastroenterology* 2020, accepted.
5. **Kelly CR**, Ananthakrishnan A. Manipulating the Microbiome with Fecal Transplant to Treat Ulcerative Colitis. *JAMA* Jan 15th 2019.
6. **Kelly CR**, Allegretti JR. FMT in IBD: What Have We Learned? *Digestive Disease Science*. 2017 Oct;62(10):2618-2620.

7. Fischer M, Phelps E, Kao D, Huiping X, **Kelly C**. Response to Bodiwala and Skole. *Am J Gastroenterol* 2017, 112(2)391-92.
8. Kelly CR, Kim A, Laine L, The AGA's Fecal Microbiota Transplantation National Registry: An Important Step toward Understanding Risks and Benefits of Microbiota Therapeutics. *Gastroenterology* Mar;152(4):681-684
9. Grinspan A. **Kelly C**. FMT for IBD: Not Just Yet. Editorial. *Gastroenterology* 2015.
10. Kelly C. A simple faecal preparation protocol to make FMT easier, cheaper and more accessible. Editorial. *Aliment Pharmacol Ther* 2014.
11. Kelly CR: FDA Oversight of FMT is Necessary. *AGA Perspectives*, February 2014.
12. Alang N. **Kelly C**. Pitfalls in *Clostridium difficile* Diagnosis. *New York Medical Journal*. 2014.

BOOKS AND BOOK CHAPTERS

1. Rupawala A, **Kelly CR** "Decision: Which *C.difficile* Infection patients are Appropriate for FMT?" (The 6 D's of FMT: A Primer for Clinicians from Decision to Discharge and Beyond, SLACK Incorporated 2019
2. Fine S, **Kelly CR** "FMT in *Clostridium difficile* and Other Potential Uses." *The Microbiota in Gastrointestinal Pathophysiology* Elsevier 2017
3. **Kelly C**: "Food Poisoning" In: Sleisenger & Fortran's *Gastrointestinal and Liver Disease* 10th ed. 2015.
4. **Kelly C**, Degli Esposti S: Hyperemesis. In: McGarry KA, Tong IL, eds *5-Minute Consult Clinical Companion to Women's Health*. Philadelphia, PA: Lippincott, Williams and Wilkins; 2007:238-240.
5. **Kelly C**, Wands J: "Molecular Biology of Liver Carcinogenesis and Hepatitis." Blumgart: In: *Surgery of the Liver, Biliary Tract and Pancreas*, 4th ed.

OTHER PUBLICATIONS

1. Kassam Z, Dubois N, Ramakrishna B, Qazi T, Smith M, **Kelly CR**, Fischer M, Allegretti J, Budree S, Kelly C, Osman M. Donor Screening for Fecal Microbiota Transplantation. *New England Journal of Medicine*. October 30th 2019.
2. **Kelly C**. "Providence in Medicine." *Annals of Internal Medicine* June 17th 2019
3. Azimirad M, Yadegar A, Aghdai HA, **Kelly CR**. Enterotoxigenic *Clostridium perfringens* infection as an adverse event after faecal microbiota transplantation in two patients with ulcerative colitis and recurrent *Clostridium difficile* infection: a Neglected agent in donor

screening. *Journal of Crohn's and Colitis* 2019,1-2.

4. Hoffmann D, Palumbo F, Ravel J, et al. Improving regulation of microbiota transplants. *Science* 2017; 358 (6369):1390-91. Working group member:
www.law.umaryland.edu/programs/health/events/microbiota/
5. Fischer M, Phelps E, Kao D, Xu H, **Kelly C**. Response to Bodiwala and Skole. *American Journal of Gastroenterology* 2017; 112(2)391.
6. Bakow B, Ziud H, **Kelly C**. Fecal Microbiota Transplantation: Harnessing the Gut Microbiota to Treat Disease Microbe (Washington, D.C.) 10/2015; 10(10):426-430.
7. **Kelly C**. Brief commentary. *GI and Hepatology News*. July 2015.
8. **Kelly C**: "Electric Razors as a Potential Vector for Viral Hepatitis." Letter to the Editor, *The New England Journal of Medicine* 342(10:744-45, March 9, 2000.
9. **Kelly C**: "Electric Razors as a Potential Vector for Viral Hepatitis." Reply to Correspondence, *The New England Journal of Medicine* 342(24):1841, June 15, 2000.

PUBLICATIONS SUBMITTED OR IN PREPARATION

1. **Kelly CR**. Fischer M, Allegretti J, et al. American College of Gastroenterology Guidelines for Prevention, Diagnosis, and Treatment of *Clostridioides difficile* Infections. 2020. Under review
2. Gachette D, Rupawalla A, Bakhit M, Jimoh L, **Kelly C**. Fecal Microbiota Transplant by Sequential Retention Enema does not Result in Sustained Cure in Severe or Complicated *Clostridioides difficile* Infection.
3. Chen B, Perler B, Scotina A...**Kelly CR**. Prevalence of Irritable Bowel Syndrome after Fecal Microbiota Transplant for *C. difficile* Infection. *Digestive Disease Science*

ABSTRACTS, POSTERS AND ORAL PRESENTATIONS

1. Allegretti JR, **Kelly CR**, Louie T, et al. An Investigational Oral Microbiome Drug, CP101, for the Prevention of Recurrent *C. difficile* Infection: A Randomized, Placebo-Controlled, Multi-Center Trial (PRISM3). ACG 2020, Virtual. October 23-28th 2020. Oral Abstract Paper Presentation #LB2 (Late-Breaking Abstract)
2. Allegretti JR, **Kelly C**, Grinspan A. et al. Fecal Microbiota Transplantation Decolonizes *C. difficile* in Patients With Inflammatory Bowel Disease and Concomitant *C. difficile* Infection. ACG 2020, Virtual. October 23rd-28th 2020. Oral Abstract Paper Presentation.
3. Sanga M, Kelly CR. Rare Case of Toxin Positive *C. difficile* Infection Managed With Psyllium. ACG 2020, Virtual. October 23-28th 2020. Poster.
4. Hsia Katie, **Kelly CR**. Understanding the Process Leading to Fecal Microbiota Transplantation in *C. difficile*. ACG 2020, Virtual. October 23-28th 2020. Poster.

5. Hsia Katie, **Kelly CR**. Twitter Interactions Around Fecal Microbiota Transplantation Have Increased Over Time. ACG 2020, Virtual. October 23-28th 2020. Poster
6. Ward C, Dharmadhikari N, Elfanagely Y...**Kelly, C**. "Men Do Procedures and Women Manage IBS": Examining Gender Bias in Industry Marketing Interactions. ACG 2020, Virtual. October 23-28th 2020. Poster
7. Wungiranirun M, Risech-Neyman, Wang C, Grand D, **Kelly C**, Promrat K. Fecal Microbiota Transplantation in Nonalcoholic Steatohepatitis: A Case Series. Digestive Disease Week 2019. San Diego, California. Poster
8. Allegretti J, Hurtado J, Carrellas M, Marcus J, Phelps E, Wong WF, Marchesi J, Mullish B, McDonald J, Pechilvanis A, Barker G, Bianco J, Sagi S, Bohm M, **Kelly C**, Kassam Z, Grinspan A, Fischer M. The Icon Study: Inflammatory Bowel Disease and Recurrent *Clostridium difficile* Infection; Outcomes after Fecal Microbiota Transplantation. Digestive Disease Week 2019. San Diego, California. Oral Presentation.
9. Kassam Z, Dubois N, Ling K, Ramakrishne B, Qazi T, Allegretti J, Fischer M, Kelly C, Budree S, Panchal P, Osman M. Donor for Health Screening for Fecal Microbiota Transplantation: Prospective Evaluation of 15,317 Candidate Donors. Digestive Disease Week 2019. San Diego, California. Oral Presentation
10. Gachette D, Bakhit M, Rupawalla A, Jimoh L, Kelly C. Inpatient Management of Severe *Clostridium difficile* Infection using Fecal Microbiota Transplant via Retentiona enema. Digestive Disease Week 2019. San Diego, California. Poster.
11. Perler B, Chen B, Allegretti A...**Kelly C**. Long-term efficacy and safety profile of fecal transplants for the treatment of recurrent *C. difficile* infection. *ACG 2018 Annual Scientific Meeting Abstracts*. Philadelphia, Pennsylvania: American College of Gastroenterology.
12. Chen B, Perler B, Allegretti A...**Kelly C**. Prevalence of Irritable Bowel Symptoms after fecal microbiota transplant for *C. difficile*. *ACG 2018 Annual Scientific Meeting Abstracts*. Philadelphia, Pennsylvania: American College of Gastroenterology.
13. Olanrewaju J, Darrel G, Mena B, **Kelly C**. Fecal Microbiota Transplant via Retention Enema in Severe *Clostridium difficile* Infection P1890. *ACG 2018 Annual Scientific Meeting Abstracts*. Philadelphia, Pennsylvania: American College of Gastroenterology.
14. Ekekezie C, Simmons S, Perler B...**Kelly C**. Understanding the Scope of Do-It-Yourself (DIY) Fecal Microbiota Transplant (FMT) P1021. *ACG 2018 Annual Scientific Meeting Abstracts*. Philadelphia, Pennsylvania: American College of Gastroenterology.
15. Argueta E, Ekekezie C, Roussel B...**Kelly C**. Late Presenting Celiac Disease and Atypical T-Cell Lymphoproliferative Disorder P2581. *ACG 2018 Annual Scientific Meeting Abstracts*. Philadelphia, Pennsylvania: American College of Gastroenterology.
16. Roussel B, Carter V, Ekekezi C...**Kelly C**. Hemophagocytic Lymphohistiocytosis in a Patient With Crohn's Disease P1404. *ACG 2018 Annual Scientific Meeting Abstracts*. Philadelphia, Pennsylvania: American College of Gastroenterology.

17. Panchal P, Ryan E, Shrish B, Majdi O, Allegretti J, Kelly CR, Fischer M, Kassam Z. Scaling Access to Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection in the United States: A Geospatial Time-Series Analysis from 2013 to 2017. Digestive Disease Week® (DDW). June 2-5, 2018. Washington, DC.
18. Lee, R. Ekekezie C, **Kelly CR**. Investigating Racial Disparities in Treatment of *Clostridium difficile* Infections. American College of Gastroenterology Annual Meeting 2017. Orlando, FL
19. Budree S, Rao S, Allegretti J, Fischer M, **Kelly C**, Smith M, Osma M, Kassam Z. The Association of Donor Stool Consistency by Bristol Stool Scale on Microbial Profile and Clinical Outcomes of Fecal Microbiota Transplantation in *Clostridium difficile* Infection. Digestive Disease Week® (DDW). May 6-9th 2017. Chicago, IL.
20. Budree S; Elliott R, Rao S, Njenga M, Ladha A, Allegretti J, Fischer M, **Kelly C**, Osman M, Smith M, Kassam Z. Donor Stool Processing Time: The Effect on the Intestinal Microbiome and Clinical Outcomes of Fecal Microbiota Transplantation in *Clostridium difficile* Infection. Digestive Disease Week® (DDW). May 6-9th 2017. Chicago, IL.
21. Budree S, Tu E, Leith T, Allegretti J, Rao S, Day R, O'Brian K, Ling K, Fischer M, **Kelly C**, Osman M, Smith M, Kassam Z. The Association of Stool Donor Diet on Microbial Profile and Clinical Outcomes of Fecal Microbiota Transplantation. Digestive Disease Week® (DDW). May 6-9th 2017. Chicago, IL.
22. Budree S, Wong W, Tu E, Rao S, Allegretti J, Fischer M, **Kelly C**, Osman M, Smith M, Kassam Z. Do Specific Bacteria Drive Clinical Cure in Fecal Microbiota Transplantation for *Clostridium difficile* Infection?: Clinical, Microbial and Metabolomic Characterization of Universal FMT Donors. Digestive Disease Week® (DDW). May 6-9th 2017. Chicago, IL
23. Panchal P, Budree S, Tu E, Kahn S, Allegretti J, Fischer M, Kelly C, Kassam, Z, Osman M. Pediatric Access to Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection in the United States and the Impact of Stool Banks: A Geospatial Analysis. Digestive Disease Week® (DDW). May 6-9th 2017. Chicago, IL
24. Santiago M, Allegretti J, Aroniadis O, Brandt L, Budree S, Fischer M, Grinspan A, Kassam Z, **Kelly C**, Rosenbaum R, Timberlake S, Smith M. A Human Microbiome Disruption Index Can Identify rCDI Patients and Increases with Antibiotic Use. Oral presentation (Session: Antibiotics Impact on Gut Microbiota). ASM Microbe, New Orleans, LA. June 2017
25. Eyenbach L, Allegretti J, Aroniadis O, et al. Clearance of Vancomycin-Resistant Enterococcus Colonization with Fecal Microbiota Transplantation among Patients with Recurrent *Clostridium difficile* Infection. ID Week 2016. New Orleans, LA.
26. Jamot S, **Kelly C**, Shah S. Won the Battle, Lost the War: IBD flare after Fecal Microbiota Transplantation in Recurrent *C. difficile* Infection. American College of Gastroenterology National Meeting: October 2016. Las Vegas, Nevada.
27. Rebello D, Yen E, Lio P, **Kelly C**. Unexpected Benefits: Hair Growth in Two Alopecia Patients after Fecal Microbiota Transplant. American College of Gastroenterology National Meeting: October 2016. Las Vegas, Nevada

28. Staley C, **Kelly CR**, Brandt LJ, et al. Characterization of Fecal Microbiota in Response to Heterologous Versus Autologous (Placebo) Fecal Microbiota Transplantation: Results from a Duel-Center, Randomized, Placebo-Controlled Trial. Digestive Disease Week® (DDW). May 21-24th 2016. San Diego, CA.
29. Allegretti J, Storm M, Smith M, **Kelly CR**, et al. Strain-Level Analysis of Microbial Engraftment Associated With Resolution of Recurrent *Clostridium difficile* Following Fecal Microbiota Transplantation. Digestive Disease Week® (DDW). May 21-24th 2016. San Diego, CA.
30. Sharma MR, **Kelly CR**, Kao D, et al. Inpatient Status, Severe *Clostridium difficile* Infection and Immunocompromised State Predict Failure Despite Multiple Fecal Microbiota Transplants: A Multicenter Study. Digestive Disease Week® (DDW). May 21-24th 2016. San Diego, CA.
31. **Kelly C**, Brandt L, Abt M, et al. A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Fecal Microbiota Transplantation in Patients with Recurrent *Clostridium difficile* Infection (NIH/NIDDK IR21DK0939839). American College of Gastroenterology. October 19th 2015. Honolulu, Hawaii. Late breaking abstract. *Oral presentation*
32. Fischer M, Mehta SR, Phelps E...**Kelly CR**. Predictors of Failure After Fecal Microbiota Transplantation (FMT) for the Therapy of *Clostridium difficile* Infection (CDI) American College of Gastroenterology. October 19th 2015. Honolulu, Hawaii. *Oral presentation*
33. Jackson M, Olafson S, Kelly C. A Challenging Case of Diarrhea after Fecal Microbiota Transplant. American College of Gastroenterology. October 16-21st 2015. Honolulu, Hawaii. Poster Presentation.
34. Jackson M, Olafson S, Machan J. **Kelly C**. The Spectrum of Alternate Diagnoses and Outcomes in Patients Referred for *C. difficile* Infection. Digestive Disease Week; May 16-19th 2015, Washington D.C.
35. Jackson M, Olafson S, Machan J. **Kelly C**. Characteristics, Outcomes, and Adverse Events in Patients who Underwent Fecal Microbiota Transplant for Recurrent *Clostridium difficile* Infection Using Rebiotix Microbiota Suspension.
American College of Physicians; RI Chapter Annual Meeting. May 7th 2015. *Oral Presentation*
36. Alang, N, Reinert S, Briggs E, Vaish A, Juarez L, Mannino C, **Kelly C**. How are Patients with *Clostridium difficile* (CDI) Infection being treated in the Hospital? Are we Following the Treatment Guidelines in Managing CDI. SHEA Spring 2015 Conference. May 14th-17th, Orlando FL
37. Kelly C, Ziud H, Kahn S. New Diagnosis of Crohn's Colitis 6 weeks After Fecal Microbiota Transplantation (FMT). 2014 Advances in IBD. Orlando, FL.
38. Pardi D, **Kelly C**, Khanna S. et al. SER-109, an oral, microbiome-based therapeutic, is efficacious for the treatment of recurrent *C. difficile* and eliminates *Enterobacteriaceae* and vancomycin-resistant *enterococci* colonizing the gut. ICAAC. September 5-9, 2014. Washington DC. *Oral presentation*

39. Fischer M, **Kelly C**, Kao D, et al. Outcomes of Fecal Microbiota Transplantation for *Clostridium difficile* Infection in Patients with Inflammatory Bowel Disease. American College of Gastroenterology. Oct 17-22, 2014. Philadelphia, PA.
-2014 ACG Presidential Poster Award
40. Wilson D, Rhani D, **Kelly C**. Safety Outcomes after Fecal Microbiota Transplantation (FMT) for *C. difficile* Infection (CDI). American College of Gastroenterology. Oct 17-22, 2014. Philadelphia, PA.
41. Freeman S, Mao E, Shah S, **Kelly C**. A Case of *C. difficile* enteritis treated with fecal microbiota transplantation. American College of Gastroenterology. Oct 17-22, 2014. Philadelphia, PA.
42. Sahil K, Pardi D, **Kelly C**, et al. Clinical evaluation of SER-109, a rationally designed, oral microbiome-based therapeutic for the treatment of recurrent *Clostridium difficile*. James W. Freston Single Topic Conference, Therapeutic Innovations in the Microbiome Research and Technology: A Further Look into Fecal Microbiota Transplantation. Chicago, IL. August 16-17, 2014
43. Agrawal, M, Aroniadis O, Brandt L, **Kelly C**. et al. A Long-Term Follow up Study of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) for Recurrent/Severe/Complicated *C. difficile* Infection (CDI) in the Elderly. Digestive Disease Week May 3-6, 2014. Chicago, IL. *Oral presentation*
44. Ihunnah C, **Kelly C**. et al. "Fecal Microbiota Transplantation (FMT) for Treatment of *Clostridium difficile* Infection (CDI) in Immunocompromised Patients." American Journal of Gastroenterology 2013:S179. American College of Gastroenterology. Oct 11-16, 2013. San Diego CA.
-Winner of the ACG Governor's award for excellence in clinical research
- Oral presentation at Presidential Plenary
45. Mao E, **Kelly C**, Machan J. Apparent Racial Differences in *Clostridium difficile* Infection Risk may be Attributable to Healthcare Access. American Journal of Gastroenterology 2013:S174. American College of Gastroenterology. October 11-16, 2013. San Diego, CA.
-2013 ACG Presidential Poster Award
46. Patel S, **Kelly C**. Colombel J, Atreja A. Comparative Cost Analysis of Fecal Microbiota Transplant and Antibiotic Treatment for Recurrent *Clostridium difficile* Infection. American Journal of Gastroenterology 2013:S169. American College of Gastroenterology. October 11-16, 2013. San Diego, CA.
47. Brandt L, Aroniadis O, Greenberg A, Borody T, Finlayson S, Furnari, V. **Kelly C**. "Safety of Fecal Microbiota Transplantation (FMT) in Immunocompromised (IC) Patients with Inflammatory Bowel Disease (IBD)." American Journal of Gastroenterology 2013:S556. American College of Gastroenterology. Oct 11-16, 2013. San Diego CA.
-2013 ACG Presidential Poster Award
48. Ochieng M, Matoso A, **Kelly C**. "An Unusual Case of Pheochromocytoma Presenting as Ischemic Colitis in a Young Male with Bloody Diarrhea." American Journal of

Gastroenterology 2013:S412. American College of Gastroenterology. October 11-16, 2013. San Diego, CA.

-2013 ACG Presidential Poster Award

49. Gosalia A, Ochieng M, Matoso A, **Kelly C**. "Pitch Black: A Case of Pseudomelanosis Duodeni." American Journal of Gastroenterology 2013:S311. American College of Gastroenterology. October 11-16, 2013. San Diego, CA.
50. Aroniadis OC, Brandt LJ, Greenberg A, Borody T, **Kelly C**, Mellow M, Surawicz C, Cagle L, Neshantian L. Long-term follow-up study of fecal microbiota transplantation (FMT) for severe or complicated *Clostridium difficile* infection (CDI). Digestive Disease Week May 18-21, 2013. Orlando, FL
-Oral presentation
51. Zandman D, **Kelly C**, Parenteau S, Blanchard K, Reinert S, Mermel L. Race is not an independent risk factor for poor outcomes in *Clostridium difficile* infection. American Journal of Gastroenterology 2012:S. American College of Gastroenterology. October 22-24, 2012. Las Vegas, NV.
52. **Kelly C**, de Leon L, Habr F, Watson J. First Reported Complication of Fecal Microbiota Transplant: Ulcerative Colitis Flare after FMT for relapsing *Clostridium difficile* Infection. Digestive Disease Week May 19-22, 2012
-Awarded Poster of Distinction
53. Mellow M, Brandt LJ, Aroniadis OC, Kanatzar A, **Kelly C**, Park T, Stollman N, Rohlke F, Surawicz C. "Long term follow up of Colonoscopic Fecal Microbiota Transplant (FMT) for Recurrent *C. difficile* Infection." American Journal of Gastroenterology 2011:S.
-Winner of the ACG Governor's award for excellence in clinical research
- Oral presentation at American College of Gastroenterology Annual Scientific Meeting October 28-Nov 2, 2011. Washington, DC.
54. **Kelly C**, de Leon L, Kerstetter D, Okpara N. "Barriers to Greater Utilization of Fecal Bacteriotherapy for Chronic *Clostridium difficile* Infection." American Journal of Gastroenterology 2010; S135. American College of Gastroenterology. October 15-20, 2010. San Antonio, TX
55. **Kelly C**, de Leon L. "Successful Treatment of Recurrent *Clostridium difficile* Infection with Donor Stool Administered at Colonoscopy: A Case Series." American Journal of Gastroenterology 2010; S135. American College of Gastroenterology. October 15-20, 2010. San Antonio, TX
56. Abstract and Poster presentation: October 1999 Associates Competition, Massachusetts Chapter of the American College of Physicians. "Medical Therapy of Cushing's Syndrome Secondary to ACTH Producing Tumor."
57. Poster: Landacre Day, The Ohio State University College of Medicine. April 1997 "Obese Diabetic Patients Have Increased Volume, Decreased pH Gastric Contents Compared to Obese Non-Diabetic Patients."

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

1. **Kelly CR.** The Microbiome and Clinical Medicine: Innovative and Emerging Therapeutic Pathways. NEJM Group Open Forum. Expert. May 31st through June 9th.
2. **Kelly C.** Report of the Working Group on Reproductive and Middle Years. From the Conference: Moving into the Future: New Dimensions and Strategies for Women's Health Research. Sponsored by the Office of Research on Women's Health (ORA). Providence, RI. September 21-23, 2009.

INVITED PRESENTATIONS

Local

1. "The Gut Microbiome: Role in Health and Disease and New Therapeutic Opportunities." Lifestyle Medicine Conference. Johnson and Wales University. November 7th 2019.
2. "Fecal Microbiota Transplant for *Clostridium difficile* Infection: Improving Access and Improving Therapy." Infection Control Professionals of Southern New England Annual Meeting. November 7th 2018.
3. "How Involvement in Professional Societies and National Organizations can Propel your Career." Panelist. Lifting the Voices of Women in Science and Medicine. Alpert Medical School. June 14th 2018.
4. "Update on the Treatment of Clostridium difficile Infection: What the Practicing Physician Needs to Know." RI American College of Physicians Annual Meeting. Providence, RI March 28th 2018.
5. "C difficile Infection: What Housestaff Need to Know: Medical Resident Noon Conference:
 - Rhodes Island Hospital. July 10th 2017
 - Providence VA Medical Center. August 14th 2017
6. "Gut Bugs and Fecal Transplants: Targeting the Microbiome to Treat Disease" Rhode Island Hospital. February 16th 2017.
7. "Steatorrhea" Medical Resident Noon Conference.
 - Rhode Island Hospital. September 8, 2016.
 - Providence VA Medical Center. September 12, 2016.
8. "Fecal Microbiota Transplantation: Evidence, Methodology, and Challenges." Hospitalist Medicine Noon Conference. The Miriam Hospital. November 10th 2015.
9. "Fecal Microbiota Transplantation: Evidence, Methodology, and Challenges." Transplant Grand Rounds. Rhode Island Hospital. May 29th 2015.
10. "Fecal Microbiota Transplantation for *C. difficile* Infection." Surgery Grand Rounds. Rhode Island Hospital. May 12th 2015.
11. "Fecal Microbiota Transplantation: Evidence for Efficacy of FMT in Treatment of Disease." Research Week. Providence VA Medical Center. May 23rd 2014.

12. "Fecal Transplantation for *C. difficile*: Overcoming Challenges to Safely Deliver and Effective Therapy." Bryant University. Smithfield, RI. March 26th 2014.
13. "Update on *C. difficile*: From Flagyl to Fecal Microbiota Transplantation." Updates in Internal Medicine. Providence VA Medical Center. Providence, RI. February 7th 2014.
14. "Fecal Transplantation for Relapsing *C. difficile*." Rhode Island American College of Physicians Annual Meeting. May 9th 2013.
15. "Fecal Transplantation for Relapsing *C. difficile*." Rhode Island Dietetic Association Annual Spring Conference. May 7th 2013.
16. "Fecal Transplantation for Relapsing *C. difficile*." Brown Liver Research Center; weekly conference. March 7th 2013
17. "Fecal Microbiota Transplantation: Treatment Option for Relapsing *C. difficile*." Brown Pulmonary Research Seminar. Rhode Island Hospital. February 4th 2012.
18. "Fecal Microbiota Transplantation: Treatment Option for Relapsing *C. difficile*." ICPSNE Annual Conference. Warwick, RI. November 7th 2012.
19. "Fecal Microbiota Transplantation: Treatment Option for Relapsing *C. difficile*." *C. difficile* Symposium. The Miriam Hospital *C. difficile* Symposium, September 19th 2012.
20. "Irritable Bowel Syndrome: Understanding and Managing IBS" Lifespan/Rhode Island Hospital Health and Wellness Lecture Series. August 21st 2012.
21. "Fecal Microbiota Transplantation: Treatment Option for Relapsing *C. difficile*." Rhode Island Hospital Medical Grand Rounds. July 24th 2012.
22. "Dyspepsia and Peptic Ulcer Disease OB/GYN Core Curriculum Conference. Women and Infants Hospital. March 23rd, 2012.
23. "Fecal Microbiota Transplantation: Treatment Option for *C difficile*." Rhode Island Hospital GI Pathophysiology conference. June 24th 2011.
24. "Fecal Bacteriotherapy: Treatment Option for Relapsing *C. difficile*." Hasbro Children's Hospital Pediatric Gastroenterology weekly conference. January 20th 2011.
25. "Fecal Bacteriotherapy: Treatment Option for Relapsing *C. difficile*." Miriam Hospital Infectious Diseases weekly conference. September 23rd 2010.
26. Irritable Bowel Syndrome* Review and Management Update *emphasis on the pregnant patient. Memorial Hospital OB/GYN Grand Rounds. November 18th 2010.
27. "Irritable Bowel Syndrome: Diagnosis and Management Update" CME event-Management of Female Pelvic Floor Disorders: The Team Approach. March 13, 2010. Women and Infants Hospital.
28. "Dyspepsia and Peptic Ulcer Disease" OB/GYN Core Curriculum Conference. Women and Infants Hospital. April 2nd, 2010.

29. “Irritable Bowel Syndrome” OB/GYN Core Curriculum Conference. Women and Infants Hospital. February 16th 2007.
30. “Irritable Bowel Syndrome” at the East Greenwich W&I Satellite office, April 3, 2007.
31. “Irritable Bowel Syndrome” at the Swansea W&I Satellite office, April 18, 2007.

Regional

1. “Fecal microbiota transplantation: indications, methodologies, mechanisms and outlook.” Mississippi GI Society Annual Meeting. February 1st 2020.
2. “Update of fecal microbiota transplantation: indications, methodologies, mechanisms and future perspectives.” GI Grand Rounds. University of Wisconsin, Madison September 24, 2019
3. “Update of fecal microbiota transplantation: indications, methodologies, mechanisms and future perspectives.” Applied Pharmaceutical Analysis, Boston, MA 09/09/19
4. “Gut Bugs and Fecal Transplants: Targeting the Microbiome to Treat Disease” University of Connecticut GI Grand Rounds. Farmington CT. April 4th 2018.
5. “Gut Bugs and Fecal Transplants: Targeting the Microbiome to Treat Disease” Applied Pharmaceutical Analysis. Providence, RI. September 20th 2017.
6. “*C. difficile* and Fecal Microbiota Transplant: A Clinician’s Perspective.” Genomics and Society: Expanding the ELSI Universe. The Jackson Laboratory for Genomic Medicine and UConn Health, Farmington CT. June 6th 2017
7. “Fecal Transplant is Useless in IBD”, Inflammatory Bowel Disease: The Art and the Science in the Diagnosis and Treatment in 2015 Conference, Boston, MA, September 19, 2015.
8. “Fecal Microbiota Transplantation: Evidence, Methodology and Challenges.” Medical Grand Rounds. Loyola University Medical Center, Maywood, IL. September 15th 2015.
9. “Fecal Microbiota Transplantation: Evidence, Methodology and Challenges.” Medical Grand Rounds. University of Massachusetts, Worcester, MA. April 2nd, 2015.
10. “Fecal Microbiota Transplantation: Evidence, Methodology and Challenges.” Lenox Hill Hospital. New York, NY. January 22nd 2015
11. “Fecal Microbiota Transplantation: Evidence for Efficacy of FMT in Treatment of Disease.” Visiting Professor Lecture. University of Pittsburgh. Pittsburgh, Pennsylvania. April 11th, 2014.
12. “Update on *C. difficile*: From Flagyl to Fecal Microbiota Transplantation.” Pittsburgh Gut Club. April 10th, 2014.

13. "Fecal microbiota transplantation for *C. difficile*: Overcoming Challenges to Safely Deliver an Effective Therapy" Division of Gastroenterology Research Conference. Mt. Sinai School of Medicine. New York. October 4th 2013
14. "Fecal microbiota transplantation for *C. difficile*: Overcoming Challenges to Safely Deliver an Effective Therapy" Division of Gastroenterology Research Conference. Yale University School of Medicine. New Haven, Connecticut. September 24th 2013
15. "Fecal Microbiota Transplantation for Recurrent *C. difficile* Infection." Berkshires Medical Center. Pittsfield, MA. April 5th 2013.
16. "Fecal Microbiota Transplantation: Treatment Option for *C difficile*." University of Massachusetts Worcester Department of Gastroenterology, Worcester, MA January 22nd 2013.
17. "*C. difficile* update." Newport Hospital Grand Rounds. Newport, RI March 1st2013.
18. "Fecal Microbiota Transplantation: Treatment Option for Relapsing *C. difficile*." Medical Grand Rounds, Cooley Dickenson Hospital, Northampton, MA. January 27th 2012.
19. "Fecal Microbiota Transplantation: Treatment Option for *C difficile*." Medical Grand Rounds, Charlton Memorial Hospital, Fall River, MA. April 24, 2012.
20. "Fecal Microbiota Transplantation: Treatment Option for *C difficile*." Medical Grand Rounds, Newport Hospital, Newport, RI. May 10th 2012.

National

1. "Comments on behalf of the American Gastroenterological Association." Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection not Responding to Standard Therapies; Public Hearing. United States Food and Drug Administration. November 4th 2019.
2. "*C difficile*: Diagnosis and Management." American College of Gastroenterology Eastern Regional Postgraduate Course. Washington, D.C. June 8th 2019.
3. "Fecal Microbiota Transplant: Who, When, Why and How." Digestive Disease Week. San Diego California, May 20, 2019
4. "*C. difficile*: Diagnosis and Management." American College of Gastroenterology Annual Spring Symposium. Naples, FL. March 2nd 2019.
5. "FMT: How to Best Deliver Therapy." American College of Gastroenterology Southern Regional Postgraduate Course. Nashville, TN December 2nd 2018.
6. "Fecal Microbiota Transplant in *C. difficile* infection." American College of Gastroenterology Annual Meeting. Philadelphia, PA. October 9th 2018
7. "Probiotics, Antibiotics and Stool Transplants: A Gut Hack, Manipulating the Microbiome." American College of Gastroenterology Annual Meeting. Philadelphia, PA. October 10th 2018

8. "Overview of Controlled Studies using FMT for Prevention of *C. difficile* Infection." Science and Regulation of Live Microbiome-based Products Used to Prevent, Cure or Treat Diseases in Humans; Public Workshop. US Food and Drug Administration and National Institute of Allergy & Infectious Diseases. September 17th 2018
9. "FMT for *C. difficile*: Improving Access and Improving Therapy." Digestive Disease Week. Washington DC. June 5th 2018.
10. "Update in the Treatment of *Clostridium difficile* Infection." American College of Gastroenterology Best Practices Course. Las Vegas, Nevada. January 27th 2018.
11. "Best Practices in FMT: Administration, Formulation, Protocol." Crohn's and Colitis Congress. Las Vegas, Nevada. January 18th 2018.
12. "Microbiome Manipulation in IBD, IBS and Other Disorders." World Congress of Gastroenterology @ ACG 2017. Orlando, FL. October 17th 2017.
13. "Gut Bugs and Fecal Transplants: Targeting the Microbiome to Treat Disease" Spondyloarthritis 2017: Unmet Needs Conference III. National Institutes of Health, Lister Hill Center Auditorium, Bethesda, MD. September 15th 2017
14. "What is the Best Way to Perform FMT?" Committee Sponsored Symposium. Digestive Disease Week; Chicago, IL. May 7th 2017
15. "*C. difficile* and Beyond. What does the Future Look Like?" Focused Clinical Update. Digestive Disease Week; Chicago, IL. May 7th 2017
16. "*Clostridium difficile*: What the Hospitalist Needs to Know." American College of Physicians Annual Meeting. San Diego, CA. April 1st 2017.
17. "FMT in IBD and Other Conditions: What Is the Evidence? American College of Gastroenterology Annual Scientific Meeting 2016; Las Vegas, Nevada. October 19th 2016.
18. "Fecal Microbiota Transplant in Clinical Practice." Anaerobe Society of Americas. Anaerobe 2016. Nashville, TN. July 13th, 2014.
19. "Fecal Microbiota Transplantation in Humans: Indications, Methodologies, Mechanism and Outlook." American College of Veterinary Internal Medicine. Denver, CO. June 9th 2016.
20. "*C. difficile* Diagnosis and Management." Focused Clinical Update Session. Digestive Disease Week; San Diego, CA. May 23rd 2016
21. "The Benefits and Risks of FMT for *C. diff.*" Translational Symposium. Digestive Disease Week; San Diego, CA. May 24th 2016
22. "New Paradigms in the Management of *C. difficile* Infection." American College of Gastroenterology 2015 Annual Postgraduate Course. Honolulu, Hawaii. October 18th 2015.
23. "Bringing FMT to Your Practice: How to do it." American College of Gastroenterology Regional Postgraduate Course. Boston, MA. June 14th 2015.

24. “Current Role of FMT to Treat IBD.” Digestive Disease Week; Washington, DC. May 19th 2015.
25. “*Clostridium difficile*: From the Simple to the Complicated.” American College of Physicians Annual Meeting. Boston, MA. May 2nd 2015.
26. “Fecal Microbiota Transplantation for *C. difficile* Infection.” *Clostridium difficile* Treatment - State of the Art Symposium. IDWeek. Philadelphia, PA. October 8th 2014.
27. “Implementing FMT Protocols for Refractory CDI.” 2014 James W. Freston Conference: Therapeutic Innovations in Microbiome Research and Technology: A Further Look into Fecal Microbiota Transplantation. Chicago, Illinois. August 16 & 17th 2014.
28. “In the Trenches: Fecal Microbiota Transplantation and Clinical Trials.” American Society for Microbiology Annual Meeting. Boston, Massachusetts. May 18th, 2014.
29. “FMT: Challenges, Obstacles and Future Horizons”
Meet the Professor Lunch: Digestive Disease Week; Chicago, Illinois. May 4th 2014
30. “*C. difficile* Infection and Fecal Microbiota Transplant”
State of the Art Lecture: Digestive Disease Week; Chicago, Illinois. May 4th 2014.
31. “Fecal Transplantation for Relapsing *C. difficile*” AGA Clinical Symposium, Digestive Disease Week; Orlando, Florida. May 20th 2013.
32. “Fecal Microbiota Transplantation: Overcoming Challenges to Safely Deliver and Effective Therapy. Fecal Microbiota Transplantation: Scientific and Regulatory Issues. Center for Biologics, Evaluation and Research (FDA) and the National Institute for Allergy and Infectious Diseases (NIH). Lister Hill Auditorium, National Institutes of Health. May 3rd 2013.
33. “Fecal Microbiota Transplant.” AGA Technology Summit. “Fostering Innovation and Technology in Digestive and Metabolic Diseases.” Palo Alto, CA. March 16th 2013.

International

1. “Update on Fecal Microbiota Transplantation: Indications, Methodologies, Mechanisms and Future Perspectives.” Korean Society of Gastroenterology Annual Meeting. Seoul, Korea. April 21st 2019.
2. “Introduction to the FMT National Registry: Engaging physicians and patients in scientific investigation around the gut microbiome.” Korean Society of Gastroenterology Annual Meeting. Seoul, Korea. April 20th 2019.
3. “Fecal Microbiota Transplant: Short Report from Workshop.” Gut Microbiota for Health World Summit. Rome, Italy March 11th 2018
4. “Fecal Microbiota Transplant: Short Report from Workshop.” Gut Microbiota for Health World Summit. Paris, France March 12th 2017.

5. "Gut Bugs and Fecal Transplants: Targeting the Microbiome to Treat Disease"
The F.M. Hill Lecture, Visiting Professorship, Women's College Hospital, Toronto, Canada. November 16th 2016.
6. "Fecal Microbiota Transplantation: Evidence, Methodology and Challenges." Third International Congress of Translational Research in Human Nutrition: Intestinal Microbiota and Chronic Diseases. Clermont-Ferrand, France June 26th 2015
7. "Fecal Microbiota Transplantation Workshop Overview"
Gut Microbiota for Health World Summit 2015. Barcelona, Spain. March 15th 2015
8. "Fecal Microbiota Transplantation: Evidence, Methodology and Challenges." 11th Annual Meeting of the Japan Gastroenterological Association. Tokyo, Japan. February 14th 2015.
9. "Fecal Microbiota Transplantation: Methodology and Technical Issues." United European Gastroenterology Week. Vienna, Austria. October 21st 2014.
10. "Fecal Microbiota Transplantation for *C. difficile* Infection: Regulatory and Practical Issues" Gut Microbiota for Health World Summit 2014. Miami, Florida. March 8th 2014.
11. "Fecal Microbiota Transplantation: Evidence for Efficacy of FMT in Treatment of Disease." Gut Microbiota for Health World Summit 2014. Miami, Florida. March 9th 2014.

Other

1. "Bariatric Surgery and a Baby on Board?" Advances in Women's Health, XM Radio, January 19, 2009.

PRIOR RESEARCH EXPERIENCE

Providence VA Medical Center, Department of Gastroenterology-July 2004-June 2006

Clinical Research Project-Mentor/Principle Investigator: Dr. Kittichai Promrat

We conducted a clinical study looking at the frequency of abnormal liver tests and non-alcoholic fatty liver disease in patients taking second-generation antipsychotic medications.

Boston University Medical Center, Department of Gastroenterology-August/September 2001

Research Elective-Laboratory of Dr. M. Michael Wolfe

I assisted in a series of projects investigating the effect of COX-2 inhibition on colon cancer metastases.

Ohio State University, Department of Anesthesiology-Summer/Fall 1996

Research Scholarship-clinical study

This study was done to compare the volume and pH of gastric contents in diabetic vs. non-diabetic obese patients during induction of anesthesia.

RESEARCH GRANTS (Completed)

08/12-07/14 NIDDK1R21DK093839-01A1 PI

Fecal Microbiota Transplantation for Relapsing *C. difficile* Infection. \$275,000

08/2014-06/30/2018
Assembly Biosciences
Alterations in Gut Microbiota and Metabolism Following FMT for Recurrent *C. difficile* Infection.

PI
\$66,360.69

Awarded March 11, 2016
Rhode Island Foundation
Medical Research Grant #20154140
Fecal Microbiota Transplant by Enema in Severe *Clostridium difficile* Infection

PI
\$25,000

RESEARCH GRANTS (Current)

07/16-06/21 NIAID 1R24AI118629-01A1 Co-PI (Wu, Kelly, Laine)
Fecal Microbiome Transplant National Registry \$2,778,96

01/01/17-12/31/19 Co-Investigator
Crohn's and Colitis Foundation
PI (Allegretti)
ICON study: Inflammatory Bowel Disease and Recurrent *Clostridium difficile* Infection:
Outcomes after Fecal Microbiota Transplantation

PCORI Grant: 10053886 Site Investigator
PI (Lewis)
DINE-CD
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific
Carbohydrate and Mediterranean Diets to Induce Remission in Patients with Crohn's Disease

INDUSTRY FUNDED RESEARCH

06/2018-Present
Finch Therapeutics Site Investigator
PRISM 3 Trial: The trial will evaluate the safety and effectiveness of CP101 (the study drug) to
prevent recurrence of *C. difficile* infection compared against placebo.

07/2015-07/2016
Seres Health Site Investigator
ECOSPOR: Phase 2 clinical study focused on the safety and efficacy of SER-109, a drug for the
potential prevention of recurrent *Clostridium difficile* infection (CDI) in adults who have had
three or more episodes of CDI within the previous nine months.

10/2013-07/2015
Seres Health Site Investigator
SERES 001: A Single-Arm Study of Modified Fecal Microbiota Transplant Delivered via Oral
Administration for the Treatment of Recurrent *Clostridium difficile*

06/2014
Actelion Site Investigator

IMPACT: Randomized, double-blind study comparing the efficacy and safety of novel antibiotic oral cadazolid (250 mg, twice daily) versus that of vancomycin (125 mg, 4 times daily) in patients with *Clostridium difficile*-associated diarrhea.

INDEPENDENTLY FUNDED AND UNFUNDED RESEARCH

01/16-18 Site-PI
Safety of fecal microbiota Transplantation: OpenBiome Outcomes and Longitudinal follow-up (STOOL) for recurrent Clostridium difficile infection
 Prospective open label clinical trial

07/15-17 Co-PI
Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis (NASH)
 Open label pilot study

01/16-10/2018 Mentor/Senior Author
Investigating Racial Disparities in Treatment of C. difficile Infection
 This is a cross-sectional, local study using a survey that will be distributed to patients and primary care physicians (PCPs) in both insured and uninsured populations. The specific aims of this study are to determine patient and provider knowledge and concerns around fecal microbiota transplant.

UNIVERSITY TEACHING ROLES

| | |
|-------------------------|--|
| 2017-present | Lecturer Alpert Medical School of Brown University Gastroenterology Course |
| 2016-present | Noon conference lecturer Rhode Island Hospital and Providence VA Medical Center |
| 2009-2014, 2016-present | Small group facilitator. Gastroenterology course Brown University Alpert School of Medicine |
| July 2006-2014. | Lecturer. OB/GYN Core Curriculum. Women and Infants Hospital. |

HOSPITAL TEACHING ROLES

| | |
|---------------------|---|
| 2009-present | Gastroenterology service attending. Rhode Island Hospital |
| July 2006-July 2011 | Gastroenterology consultation service attending. Women and Infants Hospital. |

TRAINEES MENTORED

| Name | Year Mentored | Position |
|----------------|---------------|----------|
| Tina Parks | 2011-2012 | Resident |
| Lauren de Leon | 2011-2012 | Resident |
| Daniel Zandman | 2011-2013 | Fellow |
| James Watson | 2011-2013 | Fellow |
| Eric Mao | 2012-2014 | Resident |

| | | |
|-----------------------|-----------|--------------------|
| Chioma Ihunna | 2012-2014 | Resident |
| Sarah Freeman | 2013-2014 | Resident |
| Emily Briggs | 2013-2014 | Undergraduate |
| David Rahni | 2014 | Fellow |
| Desmond Wilson | 2014 | Resident |
| Tracey Martin | 2014-2015 | Medical Student |
| Melissa Jackson | 2014-2015 | Resident |
| Neha Alang | 2013-2014 | Hospitalist |
| Sidney Olefson | 2014-2015 | Resident |
| Hassan Ziad | 2014-2016 | Hospitalist |
| Sean Fine | 2015-2016 | Fellow |
| Raymond Lee | 2015-2017 | Resident |
| Jeff Moore | 2014-2015 | Graduate student |
| Malorie Simons | 2016 | Resident |
| Olanrewaju Jimoh | 2016-18 | Fellow |
| Chiazotam Ekekezie | 2016-19 | Resident |
| Yesenia Risech-Neyman | 2016-17 | Fellow |
| Alexander Browne | 2016-17 | Fellow |
| Elaine Wang | 2016-17 | Undergraduate |
| Mena Bakhit | 2017-19 | Fellow |
| Bryce Perler | 2017-20 | Resident |
| Brenden Chen | 2017-20 | Resident |
| Darrel Gachette | 2018-19 | Medical Student |
| Jason Pann | 2019- | Fellow |
| Christopher Ward | 2019- | Resident |
| Maheep Sangha | 2019-20 | Hospitalist |
| Juana Thomas | 2020- | Post-baccalaureate |
| Katie Hsia | 2020- | Medical Student |

CURRENT INVESTIGATOR INITIATED RESEARCH PROJECTS

Microbiome and FMT in alopecia areata
Impact of race and socioeconomic status on treatment of *C. difficile* infection
Descriptive study on the scope of DIY FMT
Fecal Transplant in severe or complicated *C. difficile* infection.
Fecal Transplant in the metabolic syndrome and NAFLD/NASH
Safety and Regulatory issues around fecal microbiota transplantation
Gut microbiota in autoimmune alopecia

MEDIA INTERVIEWS/POSTS

| | |
|----------------------------|---------------------------|
| Scientific American | Discover Magazine |
| Cleveland Plain Dealer | Providence Sunday Journal |
| Los Angeles Times | Boston Globe |
| New York Times | Turn to 10 Healthcast |
| Wired (online) | Canada Radio |
| Smithsonian Magazine | Maclean's Magazine |
| NPR: All Things Considered | Marie Claire |
| NBC | Huffington Post |
| AARP Magazine | Philadelphia Inquirer |
| Baltimore Sun | Proto (MGH magazine) |
| MD News Magazine | Washington Post |
| New Zealand Radio | Medscape Medical News |

The Daily Times; New Mexico
ABC News
BBC
EndoNurse
Helio Gastroenterology
MedPage Today
Brown Alumni Magazine

Brown Medicine
Infection Control Today
Fox News
VICE
BuzzFeed
Self magazine

Hobbies and Personal Interests

Ronald McDonald House of Providence Running Club
Travel
10 Lives Cat Rescue (Foster parent)